IMPACT (Improving Medical Practice through Advancement in Clinical Treatment) is a scientific platform providing healthcare professionals with updated health information to improve their knowledge in providing healthcare services.

The course highlights the current trends in the treatment of melanoma, focusing on personalised medicine and the evidence base for combination treatment with BRAFi + MEK inhibitor in melanoma and existing clinical trials. The course also discusses adverse event management and introduces the clinical trials that examined adjuvant therapy with checkpoint inhibitors or targeted therapy in melanoma patients with high risk of recurrence.

It is widely agreed that a multimodal approach that covers cognitive training, diet and exercise is the way to go for Dementia prevention. A/Prof Christopher Chen talks about the worldwide FINGER initiative and how it can be locally adapted, particularly in the local Singapore scene

Gut microbiota exists in a symbiotic relationship with the host, carrying an important role in development of the host's immune, metabolic and brain systems in early life. Capability of gut microbiota in promoting healthy development during childhood mainly depends on its composition.

Renowned paediatric nutrition experts Prof Yvan Vandenplas and Dr Sanjeev Ganguly discussed the role of probiotics, HMOs such as 2'FL, and optimized proteins in the growth and health of infants, as well as immune system development, in a dinner symposium sponsored by Nestle Nutrition Institute and chaired by A/Professor Anne Goh, President of the Singapore Paediatric Society.

Prof Dennis Black provides an overview of the anti-fracture efficacy and safety data of alendronate for the treatment of osteoporosis, shared updates on the latest clinical updates presented at ASBMR 2018, and shared the latest innovative buffered formulation of alendronate.

LAI antipsychotics can help improve adherence to schizophrenia therapy to minimize relapse episodes. Prof. Nagesh Pai discusses the benefits and clinical considerations of LAI antipsychotics, with a focus on aripiprazole once-monthly (Abilify Maintena®).

Rasagiline (Azilect®, Lundbeck) is an irreversible monoamine oxidase-B (MAO-B) inhibitor for the treatment of Parkinson's. It has been available in Europe and the United States for around a decade. With the approval of rasagiline in Singapore, Prof. Fabrizio Stocchi presents the pivotal clinical trials of the drug and its role in the overall management of Parkinson's.